| MAJOR REVIEW |
|
| Year : 2021 | Volume
: 33
| Issue : 3 | Page : 254-259 |
|
|
Rhino-orbito-cerebral mucormycosis in COVID 19 patients: Understanding the pathophysiology
Deepsekhar Das, Mandeep Singh Bajaj, Sujeeth Modaboyina, Sahil Agrawal
Dr. Rajendra Prasad Centre for Ophthalmic Sciences; Oculoplasty and Orbital Tumor Services, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Dr. Sahil Agrawal
Oculoplasty and Orbital Tumor Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/kjo.kjo_152_21
|
|
|
The pandemic caused by severe acute respiratory syndrome coronavirus 2 has had health implications of unprecedented magnitude. The second wave of the pandemic hit India with a tremendous rise in the number of patients requiring care not only for the viral inflammatory disease but also for secondary infections. Nearly 6–7 new patients of rhino-orbito-cerebral mucormycosis with active or resolved COVID-19 infection are reporting daily at a tertiary institute in Northern India. This another battle against an epidemic of mucormycosis, within an already established ongoing war of COVID-19 pandemic has aroused a need to understand the causal factors and implement effective prevention and control programs. The authors performed a thorough literature review in PubMed to understand the correlation between the two diseases. This review summarizes the plausible risk factors, and environmental determinants of mucormycosis in COVID-19, that are of particular importance to public health professionals.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
